Icahn School of Medicine at Mount Sinai, (MSSM)
At the Icahn School of Medicine at Mount Sinai, we are dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning, social concern, and scholarly inquiry.
We pursue innovative approaches to education, research and patient care, combining the best traditions of medicine with the principles and entrepreneurial thinking of a startup, to uncover novel insights about disease. Building this culture of innovation requires making large investments and taking a transformative approach to discovery, which means taking risks and disrupting the status quo. In this way, we are transforming the practice of medicine and reinventing medical research to produce radically better outcomes for patients.
We seek a variety of students who can contribute open-mindedness, empathy, social insight, medical, scientific, technological and engineering expertise, to change the very nature of medicine. We have developed a number of admissions and training programs to foster these advances and recruit multi-talented students from richly diverse backgrounds, in a non-traditional way.
We continually pioneer innovative approaches in our medical and graduate education curricula that instill entrepreneurism, encourage critical thinking and equip the next generation of basic and clinical scientists with cutting-edge methodological and technological skills to translate scientific discovery into practice and improve public health.
We have ambitious goals, preparing scientists, physicians, and leaders who will make significant contributions to local and global health care, remaining forever inquisitive in their quest for lifelong growth, learning, and contribution. We train in the classroom and the laboratory, at the bedside, and in the community. Our unwavering commitment to intellectual exchange, multidisciplinary teamwork, and innovation continually drives us forward in discoveries, advances, and service.
As a leader in biomedical research, we have hired accomplished scientists and executives with startup experience and melded them with Mount Sinai’s doctors and researchers, spurring new levels of collaboration among our faculty. We are an engine of discovery, creating new treatments for the patients who need them the most, working in partnership with leading high-tech companies. We are on the threshold of a new era in precision medicine, and our mission is to cure diseases once thought incurable, changing the lives of patients worldwide.
Icahn School of Medicine at Mt. Sinai
Professor Ronald GordonProfessor of Pathology & Director of Core Electron Microscopy Facility
--> High Tech – hosted online ICDNavigator using Big Data technology
Most stand-alone or embedded EMR ICD-10 solutions JUST FALL short. Majority are either using CMS GEM (General Equivalent Mapping) or relational data-base driven application or algorithms.
CMS by it own admission states a disclaimer that their ICD-9 to ICD-10 general equivalency mapping is rudimentary and UNDER NO CURCUMSTANCE SHOULD BE RELIED UPON SOLELY with ICD-10 coding. The facts are few ICD-9 map one on one to ICD-10 and the explosion from 13,000 ICD-9 CM to 68,000 ICD-10CM codes makes it apparent that GEMS is at a best a LIMITED guide toward the transitions from ICD-9CM to ICD-10CM.
EMR vendors on the other hand rely on antiquated old-school, pre-BIG DATA information technologies like SQL relational databases that serve well defined data well as most corporations have in the past.
Post Internet era however, unstructured DATA seems to be dominating databases what with blogs, social media, XML and user driven data that would be impossible to contain in traditional SQL relational database tables. Imagine the folly of Google using relational data bases instead of it page-ranking, search driven algorithms to catalog the billions of Internet web pages.
ICDNavigator recognized the absurdity of such an approach with ICD-10 & therefore designed and developed using BIG DATA driven NoSQL, search indexing technologies like SOLR, Apache Lucene, etc.
ICDNavigator has managed to do what most big EMR vendors or stand-alone physician practice management software CAN NOT DO, i.e develop a sophisticated interactive tool that allow ALL data related to a ICD-10 codes produced from a diagnoses keyword search that works like Google. That aside, the same interactive user screen driven application can be ‘packaged and embedded’ as RESTFUL API programming interfaces into virtually any site or within any application.
Another HUGE advantage to the unstructured DATA approach ICDNavigator has taken is that the hosted application is customizable via simple KEYWORD addition by the use at the site WITHOUT ANY PROGRAMMING. Doing so allows us to LET USERS at the site create simulated Superbills, for example, by merely associating KEYWORDS entered by physician or staff thus creating site or physician specific ICD-10 codes matched to CPT codes used to bill the provider services with.
--> High Touch – acknowledging fully well that no software solution ONLY will do the job
ICDNavigator is truly one of a kind in this respect. Aside from offering a FREE version of ICDNavigator or an OPTIONAL monthly fee based PREMIUM ICDNavigator version, we back up our solution with our ICDNavigator Call Center staffed ICD-10 medical coders to assist either thru a phone call or Live Chat/Screen-Share Feature.
Imagine getting stuck with a specific code and not knowing where to for FAST and ACCURATE on the spot HELP with choosing the very specific ICD-10 code you need based on diagnoses or being informed additional High Risk codes you can bill may be included if applicable from case to case.
Only ICDNavigator offers on-demand, LIVE HELP WHEN YOU NEED IT from our remote ICD-10 coders who cn walk you through how ICDNavigator works for specific search or even general ICD-10 problems specific to your need ICDNavigator notwithstanding.
ICV hosts events which bring together the CEOs of private and public growth companies and family offices and fund investors in a collaborative and safe environment. In one year, our events grew sixfold in attendance, without advertising; we grew because of the quality of the people.
Our experience as investors attending conferences and group formats in the financial industry has shown us that most company outreach events have the same feel. Overcrowded with those that inhibit the networking process and rapid fire presentations by CEOs who then race off with little to no substantive interaction after the fact, these experiences seem to leave investor attendees with unanswered questions about the top person in command, the investment opportunity, or why it can’t be done better. We believe it can.
ICV’s response to these engagement gaps at most investor events have been to create a novel medium for both companies AND investors. Whilst presentations remain at the core of the agenda, the pace is much more relaxed and designed to allow investor attendees to get to know management and fellow investors without the distraction of service provider booths and sponsorship talks. The focus shifts exclusively to listening to company presentations while building rapport and relationships through group Q&A and due diligence sessions following each CEO presentation. Companies are carefully curated for quality, with most sourced by investor attendees or based on their investment criteria, to ensure that the attendees are seeing the kind and quality of company they seek.
No more ten minute speed dating with ICV, we give investors two days in an intimate environment to ask all their questions and to see company management in many different settings. When it comes to investing, ICV believes that with a more complete picture of a company and especially its leaders, investors can feel more confident that their returns will be more secure.
Events, Retreats, Roadshows, Research
IM Strategic Partners
Ideas Matter. Throughout all of human existence, great ideas have caused tectonic shifts in the way we think, live, work, play, and heal. But having a great idea isn’t enough. Great ideas must be nurtured, developed, and driven with singular focus and relentless passion.
IM Strategic Partners (“IMSP”) was founded on the principle that strategic thinking must be coupled with strategic execution to achieve success… and a little luck along the way is nice, too.
Recognizing the changing landscape of healthcare, and health and wellness generally, IMSP was founded by Chance Gibson in 2008 on the principle that the challenges we face are too big for any one organization, or even an entire industry sector, to solve alone. Effectively addressing the issue of the health of America requires the collaboration of traditionally non-traditional partners. Insurance companies must partner with fitness companies, food companies must partner with tech companies, beverage companies must partner with healthcare professional societies, and everyone must learn to work within an ever-changing regulatory environment.
Mr Chance GibsonPresident
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer.
The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells.
The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.
Immune is headquartered in the U.S., with its primary research and development facilities in Israel.
Boris ShorExecutive Director
- Indigo designs, manufactures and supplies innovative dietary supplements focused on gastrointestinal tract (GIT) pathologies and conditions or deficiencies requiring specific clinical nutrition
- Gynov, Indigo's sister company, applies the same rules of design and manufacturing for gynecological / obstetrics sphere
- Gastroenterology / Hepatology
- Infectious Diseases - Vaccines
- Nutrition and Weight Loss
- Obstetrics/Gynecology (Women's Health)
Besides opportunistic developments, our R&D aims at producing new generation probiotics / synbiotics combining a selection of relevant strains in relation to the progresses on microbiota, a microencapsulation technology promoting the survival and the production of molecules of interest, and a pharmaceutical macro-encapsulation vectorizing active ingredients to the therapeutic target
Indigo addresses medical problems or conditions which currently lack of efficient or well-tolerated solutions. Besides, Indigo provides a clear rational while exploiting the potential of probiotics / synbiotics still faces some uncertainty among healthcare professionals.
Gynov addresses obstetrical issues for which currently available medications are contra-indicated. Thus, Gynov conceives specialized dietary supplements based upon high-quality GRAS ingredients that have demonstrated their efficacy for Gyn/Obst issuesTarget market segments
- Irritable bowel disease (IBD)
- Prevention & treatment of diarrheas
- Dialysis for end-stage renal failure
- Fertility & obstetrics
- Robust medico-scientific background
- High manufacturing & product quality (GMP)
- Exclusive promotion towards medical doctors
- High value academic partnerships
Dental and Oral Health
Gastroenterology / Hepatology
Infectious Diseases - Vaccines
Ivd / Diagnostics
Nutrition and Weight Loss
Obstetrics/Gynecology (Women's Health)
Otolaryngology (Ear, Nose, Throat)
Your innovative solution
Inferential provides statistical expertise and delivers results and statistical reports for any type of study incl clinical, NIS, health-economics, epidemiology
While health authorities are more and more demanding in terms of data quality and study standards, most pharmaceutical companies own less and less skilled statistical resources. Inferential acts as the client's own statistical department or an extension thereof.
1)Pharmaceutical companies 2)Biotechs 3) Device 4) Cosmetics and nutrition 5) Vet
1) Hign expertise with low overhead costs 2) Broad experience in both US and EMEA regulatory context
Infusion Pharma Consulting specializes in the orphan drug, hospital therapeutics and specialty biopharma markets. Our key capabilities include strategic pricing and market access, business development, and brand strategy, supported by specialty markets research.
We are leaders in the orphan drug and rare disease market and serve clients on four continents and in 12 countries. Our clients range from start-ups to Top 5 companies.
We look forward to discussing your needs.